See our new webpage about the GA-map® Dysbiosis Test
Visit page
Skip to content
Genetic Analysis
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us
Genetic Analysis
  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us

News

Genetic Analysis strengthens and future-proofs the organization

2023-01-312023-01-31

Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD

2023-02-022023-01-27

Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand

2023-01-262023-01-19

Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India

2023-01-262023-01-16

Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map® technology in Thailand

2023-01-262022-11-30

Genetic Analysis AS announces the outcome of the warrant exercise

2022-11-21

Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe

2022-11-152022-11-07

Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis

2022-11-02

Interim report January – September 2022

2022-11-01

Interim report January – June 2022

2022-08-18
Post navigation
Older posts
Page1 Page2 … Page4 Next →

Genetic Analysis AS is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Contact

Phone: +47 48 32 16 10
E-mail: info@genetic-analysis.com
Address: Genetic Analysis AS, Ulvenveien 80B
0581 Oslo, Norway

Open Google Maps
Connect

LinkedIn

Facebook

Twitter

Navigate

Contact Us

Terms of Use

Privacy Policy

© 2023 Genetic Analysis

  • Home
  • About us
    • How we work
    • Management
    • Board of Directors
    • Partnerships
  • Products
    • Service Products
      • The GA-map® Dysbiosis Test Lx
      • The GA-map® COVID-19 Fecal Test Kit
    • Lab Products
      • The GA-map® Dysbiosis Lx reagent kit
      • The GA-map® COVID-19 reagent kit
  • News
    • Press Releases
    • News
  • Investors
    • Financial Reports
    • Financial Calendar
    • Share Information
    • Analyst Coverage
    • IPO 2021
    • Corporate Governance
    • Primary Insiders
    • IR Contacts
  • Order
  • Contact us